listed IMPACT jumps as EC approves Senaparib for ovarian cancer treatment

By Reuters News

** Shares of IMPACT Therapeutics Inc 7630.HK jump as much as 27.9% to HK$11.93, their highest level since October 22

** Stock last up 15.1%, on course for the biggest one-day pct gain since September 21 in the third straight session of gains

** China-based pharmaceutical products developer says European Commission has granted approval for its self-developed innovative drug Senaparib for maintenance treatment of advanced epithelial ovarian, fallopian tube and primary peritoneal cancer

** Company says it is advancing the clinical and regulatory development of senaparib globally, and it is pursuing life cycle management for Senaparib, exploring combination therapy opportunities, and expanding into multiple indications

** Since debut on May 13, stock down 46.6% from HK$20.10 apiece offer price

** YTD, Hang Seng Biotech Index .HSBIO up 0.8%

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.